



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/571,241	03/09/2006	Rajendra K. Joshi	08201.0065-00000	9619
65779	7590	09/21/2009	EXAMINER	
BIOGEN IDEC / FINNEGAN HENDERSON, LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413				HOLLOMAN, NANNETTE
ART UNIT		PAPER NUMBER		
		1612		
NOTIFICATION DATE			DELIVERY MODE	
09/21/2009			ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

Lauren.Stevens@finnegan.com
Regional-Desk@finnegan.com

Office Action Summary	Application No.	Applicant(s)	
	10/571,241	JOSHI ET AL.	
	Examiner	Art Unit	
	NANNETTE HOLLOWMAN	1612	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 18 July 2009.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 27,28,33-49 and 65-84 is/are pending in the application.
 4a) Of the above claim(s) 27,28,33-49,67,70-73 and 84 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 65-66, 68-69 and 74-83 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____.

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.
 5) Notice of Informal Patent Application
 6) Other: _____.

DETAILED ACTION

This Office Action is in response to the Request for Continued Examination filed on June 18, 2009. Applicants' arguments, filed June 18, 2009, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

Response to Election/Restrictions

Applicant's election without traverse of Group (claims 27-28 and 33-49), myocardial infarct and fumaric acid dimethyl ester of formula (I) ester in the reply filed on May 09, 2008 has previously been acknowledged and is maintained.

Claims 27-28, 33-49, 67, 70-73 and 84 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Previously presented claims 27, 28, 33, 35, 36 and 42-49 have been amended to no longer read on the elected species and are withdrawn along with newly submitted claims 67, 70-73 and 84. Election was made **without** traverse in the reply filed on May 09, 2008.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 65-66, 68-69 and 74-83 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pye et al. (Am J Physiol Heart Circ Physiol, Vol. 284, 7 Nov 2002, pp.

919-926) in view of Joshi et al. (WO 02/055067, US 2004/0054001 is used as the English equivalent).

Pye et al. disclose treatment of patients during myocardial infarction with NF-kappaB inhibitors, which was shown to decrease the amount of reperfusion injury (p. 925, column 2, lines 41-44). Pye et al. differs from the instant claims insofar as it does not disclose the use of fumaric acid derivatives.

Joshi et al. disclose the use of fumaric acid derivatives as NF-kappaB inhibitors and the treatment of diseases influenced by NF-kappaB (Abstract). Joshi et al. further disclose the fumaric acid derivative, fumaric acid diethyl ester (paragraph [0020]), used in the preparation of a pharmaceutical composition in an amount of 1 to 500 mg (paragraph [0021]); wherein the composition is administered orally and in the form of micro-tablets with an enteric coating (paragraph [0023]), encompassing claims 77-82. Joshi et al. differs from the instant claims insofar as it does not disclose treating myocardial infarction.

It is *prima facie* obviousness to select a known material based on its suitability for its intended use. Also, established precedent holds that it is generally obvious to add known ingredients to known compositions with the expectation of obtaining their known function. MPEP 2144.07. Therefore, it would have been obvious to one of ordinary skill in the art to have used fumaric acid diethyl ester as the NF-kappaB inhibitor in the method of Pye et al. to treat myocardial infarction to achieve the known function of decreasing the amount of reperfusion injury motivated by the desire to use a compound known to be a NF-kappaB inhibitor as disclosed by Joshi et al.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NANNETTE HOLLOMAN whose telephone number is (571) 270-5231. The examiner can normally be reached on Mon-Fri 800am-500pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Frederick Krass can be reached on 571-272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/N. H./
Examiner, Art Unit 1612

/Frederick Krass/

Application/Control Number: 10/571,241
Art Unit: 1612

Page 6

Supervisory Patent Examiner, Art Unit 1612